The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fibroblast growth factor receptor alteration (FGFRa) status and progression outcomes of patients with advanced or metastatic urothelial cancer (mUC).
 
Sarah Fleming
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Dina Gifkins
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Waleed Shalaby
Employment - Novocure
Leadership - Poly-Med
Stock and Other Ownership Interests - Novocure
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Janssen Biotech; Jounce Therapeutics; Pfizer; Seagen; Symphogen
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Philip Rosenberg
Stock and Other Ownership Interests - Express Scripts; Gilead Sciences
 
Christopher Gaj
No Relationships to Disclose
 
Albert Crawford
No Relationships to Disclose
 
Grace L. Lu-Yao
Employment - Sun Pharma Advanced Research Company (I)
Leadership - Sun Pharma Advanced Research Company (I)
Stock and Other Ownership Interests - Merck (I)
 
Vittorio Maio
No Relationships to Disclose
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea; Bavarian Nordic; Bristol-Myers Squibb; EMD Serono; Genentech; Janssen; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.